ADC Therapeutics announces that it received a notice from the New York Stock Exchange (NYSE) on 2 January 2024 that the company has regained compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual and, as a result, will be removed from the NYSE’s non-compliant issuers list.
The company previously received a notice from the NYSE that it was not in compliance with the continued listing minimum price criteria, as the average closing price of its common shares was below $1.00 during a consecutive 30 trading-day period.
As closing price of the common shares on 29 December 2023 and the average closing price of the common shares over the 30 trading-day period ending on December 29 2023 were both above $1.00, the deficiency was cured.